Collaboration - May 11, 2015
Pelago, OmicScouts Collaborate
Pelago Bioscience AB and OmicScouts GmbH launched a commercial and scientific collaboration involving the use of the Cellular Thermal Shift Assay (CETSA™) for determination and quantification of drug-target interactions, according to BioSpace.com. Under the agreement, Pelago Bioscience grants OmicScouts use licenses to the CETSA method for mass spectrometric and proteomic applications for contract research projects […]
Collaboration - May 8, 2015
Ardelyx, AZ to Review Agreement
Shares of Ardelyx dropped in after-market trading earlier this week after the AstraZeneca partner acknowledged that its lead drug tenapanor was unimpressive in a Phase IIa study. Ardelyx, based in California, says that tenapanor missed the primary endpoint among 154 patients with Stage 3 chronic kidney disease (CKD) and Type 2 diabetes, and was unable […]
Collaboration - May 4, 2015
Recipharm, Follicum Ink Pact
Recipharm has signed an agreement of cooperation with Follicum AB prior to a clinical trial for the drug candidate FOL-005th, which is being developed to stimulate or inhibit hair growth for both men and women, without side effects. Recipharm has been commissioned to formulate and produce the product that will be used in the clinical […]
Collaboration - April 29, 2015
AZ, Celgene Tackle Blood Cancer
AstraZeneca has entered into a $450 million agreement with Celgene that will permit the U.S.-based drug firm to develop MEDI4736, AstraZeneca’s immunotherapy treatment for blood cancer. The agreement sent Celgene’s stock surging. AstraZeneca officials say the deal is a way to get the drug to market faster, according to Reuters. Blood cancer treatments eventually will […]
Collaboration - April 27, 2015
Juno, AZ Testing Cancer Remedy
Juno Therapeutics and AstraZeneca are joining forces to test their respective cancer treatments, combining new therapies designed to use the body’s immune system to combat tumors. Under the deal, the pair plans to jointly fund a Phase I study combining one of Juno’s CAR-T therapies and pair it with a promising antibody developed by MedImmune, […]
Collaboration - April 24, 2015
AZ, Amgen Switch to Psoriasis
Amgen and partner AstraZeneca are preparing to deliver U.S. and European applications for their plaque psoriasis drug brodalumab by midyear. The two companies halted tests for brodalumab as an asthma medication. Amgen outlined the news in its quarterly report, which also notes a 14 percent drop in R&D spending. “Based on the recommendation of an […]
